ArticleLiver cancer2023
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).
Registry-linked trialAbstract read
In one paragraph
Article in Liver cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06210334 (The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy), which is not on this map. Cited by 327 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
327citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Tislelizumab and Lenvatinib in the Treatment of Hepatocellular Carcinoma (HCC) With Type IV(Vp4) Portal Vein Tumor Thrombus (PVTT): A Prospective, Single-armed, Stage II Clinical Trial
Who cites it
327 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma.ESMO open · 2026Guideline
- Expert consensus regarding the clinical application of liver contrast-enhanced US with Sonazoid (Sonazoid CEUS).International journal of surgery (London, England) · 2026Guideline
- Narrow-margin hepatectomy combined with external beam radiotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Neoadjuvant therapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: an updated systematic review with meta-analysis.World journal of surgical oncology · 2025Pooled it
- Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Effect and safety of tislelizumab combined with anlotinib and radiotherapy in advanced hepatocellular carcinoma: A single-arm, single-center, phase II clinical study.Scientific reports · 2026Trial
- Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006).Nature communications · 2025Trial
- Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.Journal of translational medicine · 2025Trial
- [European journal of nuclear medicine and molecular imaging · 2025Trial
- Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial.BMC cancer · 2025Trial
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- Intraindividual comparison of 3-T and 5-T gadoxetic acid-enhanced MRI for evaluating HCC: initial findings.Abdominal radiology (New York) · 2026Article
- Conversion Resection or Direct Resection for Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicentre Study.Liver cancer · 2026Article
- Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review.Liver cancer · 2026Review
- Article
- Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).Liver cancer · 2026Article
- Non-Invasive Assessment of Microvascular Invasion Risk in Hepatocellular Carcinoma Using Liquid Biopsy: Translational Insights and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
- Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.Hepatology (Baltimore, Md.) · 2026Article
- Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: a phase III trial and biomarker analyses.Journal of the National Cancer Center · 2026Article
267 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
102 authors.
Jian ZhouLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Huichuan SunLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zheng WangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Wenming CongDepartment of Pathology, The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Mengsu ZengDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Weiping ZhouThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Ping BieInstitute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.
Lianxin LiuDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Tianfu WenDepartment of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
Ming KuangDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Guohong HanDepartment of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Zhiping YanDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Maoqiang WangDepartment of Interventional Radiology, Chinese PLA General Hospital, Beijing, China.
Ruibao LiuDepartment of Interventional Radiology, The Tumor Hospital of Harbin Medical University, Harbin, China.
Ligong LuDepartment of Interventional Oncology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhenggang RenLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhaochong ZengDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ping LiangDepartment of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China.
Changhong LiangDepartment of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Min ChenEditorial Department of Chinese Journal of Digestive Surgery, Chongqing, China.
Fuhua YanDepartment of Radiology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Wenping WangDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
Jinlin HouDepartment of Infectious Diseases, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yuan JiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingping YunDepartment of Pathology, Tumor Prevention and Treatment Center, Sun Yat-sen University, Guangzhou, China.
Xueli BaiDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Dingfang CaiDepartment of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Weixia ChenDepartment of Radiology, West China Hospital of Sichuan University, Chengdu, China.
Yongjun ChenDepartment of Hematology, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wenwu ChengDepartment of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
Shuqun ChengThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Chaoliu DaiDepartment of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
Wengzhi GuoDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yabing GuoDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Baojin HuaGraduate School, Beijing University of Chinese Medicine, Beijing, China.
Xiaowu HuangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Weidong JiaDepartment of Hepatic Surgery, Affiliated Provincial Hospital, Anhui Medical University, Hefei, China.
Qiu LiDepartment of Oncology, West China Hospital, Sichuan University, Chengdu, China.
Tao LiDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Xun LiThe First Hospital of Lanzhou University, Lanzhou, China.
Yaming LiDepartment of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, China.
Yexiong LiDepartment of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jun LiangDepartment of Oncology, Peking University International Hospital, Beijing, China.
Changquan LingChanghai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai, China.
Tianshu LiuDepartment of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiufeng LiuDepartment of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.
Shichun LuInstitute and Hospital of Hepatobiliary Surgery of Chinese PLA, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, China.
Guoyue LvDepartment of General Surgery, The First Hospital of Jilin University, Jilin, China.
Yilei MaoDepartment of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China.
Zhiqiang MengDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Tao PengDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Weixin RenDepartment of Interventional Radiology the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Hongcheng ShiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Guoming ShiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Ming ShiDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Tianqiang SongDepartment of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Kaishan TaoDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Jianhua WangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Kui WangThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Lu WangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Wentao WangDepartment of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
Xiaoying WangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhiming WangDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China.
Bangde XiangDepartment of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
Baocai XingDepartment of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
Jianming XuDepartment of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China.
Jiamei YangThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Jianyong YangDepartment of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Yefa YangDepartment of Hepatic Surgery and Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Yunke YangDepartment of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Shenglong YeLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhenyu YinDepartment of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University, Xiamen, China.
Yong ZengDepartment of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
Bixiang ZhangDepartment of Surgery, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Boheng ZhangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Leida ZhangDepartment of Hepatobiliary Surgery Institute, Southwest Hospital, Third Military Medical University, Chongqing, China.
Shuijun ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
Ti ZhangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Yanqiao ZhangDepartment of Gastrointestinal Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
Ming ZhaoMinimally Invasive Interventional Division, Liver Cancer Group, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Yongfu ZhaoDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
Honggang ZhengDepartment of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Ledu ZhouDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, China.
Jiye ZhuDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.
Kangshun ZhuDepartment of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Rong LiuDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yinghong ShiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yongsheng XiaoLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Lan ZhangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Chun YangDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhifeng WuDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhi DaiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Minshan ChenDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jianqiang CaiDepartment of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Weilin WangDepartment of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiujun CaiDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Qiang LiDepartment of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Feng ShenThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Shukui QinDepartment of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.
Gaojun TengDepartment of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Jiahong DongDepartment of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.
Jia FanLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary liver cancer, of which around 75-85% is hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China but also may reshape the nationwide diagnosis and treatment of liver cancer. Key Messages: The new guideline aims to encourage the implementation of evidence-based practice and improve the national average 5-year survival rate for patients with liver cancer, as proposed in the "Health China 2030 Blueprint."
Indexed as
ChinaDiagnosisGuidelinesHepatocellular carcinomaPrimary liver cancerTreatment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT06210334ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.